Background Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA) and different systemic autoimmune diseases. A multidisciplinary management allows optimizing handling and can help reducing its high morbidity and mortality.
Objectives To describe the characteristics of a cohort of patients with rheumatic disease-associated ILD (RHEU-ILD) controlled in a specific multidisciplinary consultation Pulmonology-Rheumatology, and to evaluate the changes produced by a joint activity on the diagnosis and/or treatment.
Methods All patients treated in the multidisciplinary consultation RHEU-ILD from September-2012 to October-2013 were included in the analysis. We collected the following data: origin of the patients, age, sex, diagnosis, debut and duration of the EPID, antibody profile, HRCT pattern, results of pulmonary function tests (PFTs), walking test, bronchoscopy and/or surgical biopsy (when needed), previous and current treatments, and any diagnostic and/or therapeutic change resulting from this consultation. The package SPSS 17.0 was used for descriptive statistics, and quantitative variables were compared using the t-test for paired samples.
Results Fifty-four patients were reviewed, 75.9% female, with a mean age of 63.56±15.40 years. Most patients came referred from Rheumatology (74.1%), since the debut of the EPID was after the diagnosis of the rheumatic disease in 50% of cases (33% simultaneous, and only 13% prior). The non specific interstitial pneumonia was the most frequent ILD (51.9%), followed by the usual interstitial pneumonia (UIP, 33.3%). The mean duration of the ILD was 5.49±5.31 years. ILD was associated, in order, to Systemic Sclerosis (24.2%), RA (20.4%), Sjögren (16.7%) and Antisynthetase syndrome (13%). The antibodies more frequently found were the ANA (33.3%), followed by anti-Ro (31.5%), RF (29.6%) and anti-Scl70 (18.5%). As for the PFTs, up to 55.6% of the patients showed a normal pattern, and only 29.6% a restrictive pattern. 22.2% of the patients showed desaturation when performing the walking test. Bronchoscopy was performed in 29 patients, while transbronchial biopsy and surgical biopsy were needed in 22 and 5 patients, respectively. A combined approach led to 4 changes of diagnosis (2 of them after surgical biopsy) and 9 changes of therapy (16.7%). Corticosteroids were the most used treatment (44%), followed by methotrexate (18.5%), rituximab (14.8%) and mycophenolate (9.3%). At follow-up, no significant change was observed on HRCT (72.2%) and/or the PFTs (baseline FVC 92.27% vs. last FVC 88.73%; p<0.107).
Conclusions The existence of a multidisciplinary consultation Pulmonology-Rheumatology can be key in the final diagnosis and/or treatment of our patients with rheumatic disease-associated ILD. A joint effort could help improving the prognosis of these patients.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.